Attendee search 

We are one of the largest independent venture investors in northern Europe managing approx. 1 billion USD. Sunstone Capital Life Science Ventures focus on drugs, diagnostics and medical devices, and we use our extensive industrial experience to guide our decisions and help our portfolio companies in their development.

Unisensor is seeking investors for the development, clinical evaluation and launch of a new instrument for antibiotic susceptibility testing.

Sepsis (blood poisoning) is a serious medical condition that in US alone kills more than 100,000 annually, surpassing the number of deaths from acute myocardial infarction (AMI), stroke, or cancer. Once detected, it is paramount to initiate the proper antibiotic therapy as soon as possible, since survival chance decrease by the hour. In addition septicaemia patients is a substantial economic burden to the hospital – according to one source up to 50.000 USD per patient. Traditional AST typically takes from 15-30 hours, and Unisensor has shown that this can be decreased to less than one hour by using our patented technology. This will not only increase the survival chance and reduce the costs, but also have the societal benefit, that the emergence of multi-resistant bacteria is reduced due to the earlier usage of the proper narrow-band antibiotic therapy.

To finance the instrument development, clinical evaluation and initial sales and marketing activities Unisensor is seeking investors to enter into a joint venture or or other financial collaboration or partnership.

We are one of the largest independent venture investors in northern Europe managing approx. 1 billion USD. Sunstone Capital Life Science Ventures focus on drugs, diagnostics and medical devices, and we use our extensive industrial experience to guide our decisions and help our portfolio companies in their development.

SEED Capital is the largest early stage venture fund in Denmark. We invest in companies within IT, Cleantech and Life Science at the seed or even pre-seed stage from Denmark and southern Sweden. We invest in classic venture companies that have a highly innovative solution and a scalable business model for entering an attractive market with a number of identified paths to exit.

Because of our strong partnership with the government funded innovation incubator DTU Symbion Innovation we are able to invest € 250-750.000 at the early stages of a company’s development, allowing them an opportunity to prove their technology and business.

Depending on capital need, SEED Capital can invest up to € 9 million in the following rounds – preferably in syndication with international investors. We take an active advisory role as an investor and will normally take the position of Chairman of the Board in the company until a skilled alternative is identified.

Medico Innovation is a public-private cluster organization that facilities medical device matchmaking, innovation partnerships, professional networks and innovation camps. We help innovators connect with the right experts at the right moments.

Novo Seeds is a life science supporting program launched by the Novo Nordisk Foundation and Novo A/S. Novo Seeds has two components, a pre-seed funding capacity and a seed financing fund. Both aim at identifying and developing the unexplored commercial potential present in academic and early stage applied research projects at universities and biotech companies within life science in Scandinavia.

The pre-seed program supports early stage projects based on ideas and results with commercial potential. Funding is given as grants in the same manner as other grants awarded by the Novo Nordisk Foundation.

The seed fund aims at supporting more advanced projects and will operate on commercial terms, i.e. support is given to projects and companies in exchange for ownership or other rights to the companies/projects. Typically, the seed program will invest in newly formed companies that are too early in their development stage to be supported by Novo A/S’ venture capital or other international investors

BioMed Community is a life science cluster in north Denmark.

The community is a collaboration between 55 MedTech companies, Aalborg University, Aalborg Hospital, the City of Aalborg and the Aalborg Co-operation. 

The main objective for BioMed Community is to foster innovation and generate growth by supporting our local entrepreneurs and enterprises engaged in health technology.

We want to improve the quality of life for 660.000 epilepsy families. (# is the western world only)

We want to give New Freedom and Peace of Mind to patients, parents, and health care professionals.

IctalCare A/S develops and markets a body-worn wireless epilepsy seizure alarm that help people with epilepsy, caregivers and healthcare professional

IctalCare 365 consist of a;
- Disposable electrode
- Reusable detector "Senses"
- Reusable A-Unit (receiver and transmitter)

Timeline;
- Launch 12.12.12 at 12.12 pm in Denmark
- Launch 12th of April 2013 in UK and Germany
- Launch 12th of April 2014 in USA
- Exit 2016

Finance;
- Expected revenue in 2016 is € 23 Million
- Positive cash flow from 2014 - 2015
- Expected EBITDA is € 9.3 Million in 2016 having a gross Margin of 55 %

Business Model
We have Sustainable Competitive Advantage using the Razor blade Model. The disposable electrodes secures a continuous sale and only IctalCare electrodes fit to the reusable "Senses" detector.

The Business Model is designed around a monthly subscription Model however buy on demand will also be possible

Medico Innovation is a public-private cluster organization that facilities medical device matchmaking, innovation partnerships, professional networks and innovation camps. We help innovators connect with the right experts at the right moments.